News | September 04, 2024
Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
Majority of organizations are looking to increase investments in public and hybrid cloud
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Subscribe To Our Newsletter & Stay Updated
